Hybribio Limited

Hybribio Limited was established in 2000 by a team of renowned professors and entrepreneurs from Hong Kong and Mainland China. The company is dedicated to innovation and technology in the field of human healthcare, focusing on the development of nucleic acid test (NAT) diagnostic kits. Through its collaborative approach across research and production, Hybribio has positioned itself as a notable player in the global biotech landscape, particularly in the area of cervical cancer screening.

The organization operates R&D centers in Hong Kong and Shanghai, underscoring a regional emphasis on scientific advancement and development. Its manufacturing base is situated in Guangdong, supporting scalable production capabilities, while customer support centers are located in Beijing, Hong Kong, and other major cities across China. This geographic footprint reflects Hybribio’s integrated model, combining research, manufacturing, and distribution to meet regional and international demand.

Hybribio’s work includes the development of cutting-edge technologies for HPV testing used in early cervical cancer screening. This focus aligns with broader efforts to enhance diagnostic accuracy, improve public health outcomes, and advance preventive healthcare through accessible, high-quality NAT-based testing solutions. While the company’s core activities center on diagnostic kit development, Hybribio’s ecosystem—spanning R&D, manufacturing, and customer support—demonstrates a comprehensive approach to biotech innovation and market delivery.

As a global biotech entity, Hybribio Limited continues to contribute to the advancement of NAT diagnostics and cervical cancer screening technologies. Its established presence in key Chinese regions and its collaboration with academic and industry partners position it for ongoing development in nucleic acid testing and related healthcare innovations.